Anti-n-Myc/MYCN antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

N-Myc also known as MYCN is a transcription factor encoded by the MYCN gene. It plays an important role in cell proliferation and differentiation. The n-Myc protein is part of the Myc family of transcription factors including c-Myc and c-Myb. n-Myc has a molecular weight of approximately 64 kDa. This protein expresses predominantly in developing tissues particularly in the brain but its expression is seen in other tissues during embryogenesis as well. This characteristic makes it important in early development and organ formation.

Biological function summary

N-Myc/MYCN functions in gene regulation by binding to E-box sequences in DNA facilitating transcription of genes essential for cellular growth and metabolism. n-Myc often forms a heterodimer with the MAX protein which enhances its DNA-binding capacity and transcriptional activity. This activity influences processes like apoptosis cell differentiation and cell cycle progression. The ncm mouse model a genetically engineered mouse with MYCN overexpression demonstrates the effects of deregulated n-Myc expression.

Pathways

MYCN significantly impacts the p53 signaling pathway and the Wnt signaling pathway. In the p53 signaling pathway n-Myc interacts with p53 and MDM2 regulating cell cycle checkpoints and apoptosis. In the Wnt pathway MYCN interplays with molecules like β-catenin to influence cell division and differentiation. These interactions highlight the role of n-Myc in maintaining cellular homeostasis and response to external signals that affect growth and division.

Associated diseases and disorders

N-Myc is closely linked to neuroblastoma and medulloblastoma aggressive forms of pediatric cancers. MYCN amplification often indicates a poor prognosis in neuroblastoma playing a role in tumor progression and resistance to therapy. In medulloblastoma overexpression of n-Myc partners with proteins like Aurora A kinase to promote oncogenesis. Targeting these protein interactions offers potential therapeutic strategies for these MYCN-related cancers.